Skip to main content

Table 2 Distribution of mRS score on D90 after randomization before and after MAIC

From: Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

Before MAIC

After MAIC

 

HUK

EDB

 

HUK

EDB

mRS 0

19.0%

22.7%

mRS 0

19.0%

20.2%

mRS 1

37.5%

44.4%

mRS 1

37.5%

40.6%

mRS 2

17.8%

12.8%

mRS 2

17.8%

12.0%

mRS 3

16.0%

10.9%

mRS 3

16.0%

19.3%

mRS 4

8.3%

6.3%

mRS 4

8.3%

4.8%

mRS 5

1.3%

2.7%

mRS 5

1.3%

3.1%

mRS 6

0.1%

0.0%

mRS 6

0.1%

0.0%

  1. D90 90 days, EDB Edaravone dexborneol, HUK Human urinary kallidinogenase, mRS modified Rankin Scale, MAIC Matching-adjusted indirect comparison